Ghrelin improves left ventricular dysfunction and cardiac cachexia in heart failure

Current Opinion in Pharmacology

Volumn 3, Issue 2, 2003, Pages 146-151

  Nagaya, Noritoshi ^a   Kangawa, Kenji ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; APPETITE STIMULANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOTROPIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; GHRELIN; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE SECRETAGOGUE RECEPTOR; HYDROCORTISONE; LEPTIN; LIGAND; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NITRIC OXIDE; PLACEBO; PROLACTIN; SOMATOMEDIN C; VASODILATOR AGENT;

BLOOD VESSEL; CACHEXIA; CARDIOVASCULAR EFFECT; DISEASE SEVERITY; DOSE RESPONSE; DRUG INFUSION; DRUG STRUCTURE; ENERGY BALANCE; FOOD INTAKE; GROWTH HORMONE RELEASE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART OUTPUT; HEART VENTRICLE; HUMAN; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN ISOLATION; REVIEW; STOMACH; VASCULAR RESISTANCE;

ANIMALS; CACHEXIA; HEART FAILURE, CONGESTIVE; HUMANS; PEPTIDE HORMONES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0037384111     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(03)00013-4     Document Type: Review

References (55)

1. Packer M, Cohn JN: Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999, 83(Suppl):1A-38A.
2. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The acute infarction ramipril efficacy (AIRE) study investigators. Lancet 1993, 342:821-828.
3. Ambrosioni E, Borghi C, Magnani B: The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995, 332:80-85.
4. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995, 333:1670-1676.
5. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI: Randomised trial of losartan versus captopril in patients over 65with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997, 349:747-752.
6. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675.
7. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996, 334:1349-1355.
8. Gottlieb SS, McCarter RJ, Vogel RA: Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998, 339:489-497.
9. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB et al.: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651-1658.
10. Pittman JG, Cohen P: The pathogenesis of cardiac cachexia. N Engl J Med 1964, 271:403-409.
11. Anker SD, Coats AJS: Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. Chest 1999, 115:836-847.
12. Levine B, Kalman J, Mayer L, Fillit HM, Packer M: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990, 323:236-241.
13. McMurray J, Abdullah I, Dargie HJ, Shapiro D: Increased concentrations of tumor necrosis factor in 'cachectic' patients with severe chronic heart failure. Br Heart J 1991, 66:356-358.
14. Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK: Tumour necrosis factor alpha in severe congestive cardiac failure. Br Heart J 1993, 70:141-143.
15. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, Harrington D, Kox WJ, Poole-Wilson PA, Coats AJ: Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997, 349:1050-1053.
16. Amato G, Carella C, Fazio S, La Montagna G, Cittadini A, Sabatini D, Marciano-Mone C, Sacca L, Bellastella A: Body composition, bone metabolism, heart structure and function in growth hormone deficient adults before and after growth hormone replacement therapy at low doses. J Clin Endocrinol Metab 1993, 77:1671-1676.
17. Fuller J, Mynett JR, Sugden PH: Stimulation of cardiac protein synthesis by insulin-like growth factors. Biochem J 1992, 282:85-90.
18. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, Poole-Wilson PA, Coats AJ: Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance in cardiac cachexia. Circulation 1997, 96:526-534.
19. Niebauer J, Pflaum CD, Clark AL, Strasburger CJ, Hooper J, Poole-Wilson PA, Coats AJ, Anker SD: Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. J Am Coll Cardiol 1998, 32:393-397.
20. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402:656-660.
21. Nagaya N, Kojima M, Uematsu M, Yamagishi M, Hosoda H, Oya H, Hayashi Y, Kangawa K: Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol 2001, 280:R1483-R1487.
22. Locatelli V, Rossoni G, Schweiger F, Torsello A, De Gennaro Colonna V, Bernareggi M, Deghenghi R, Muller EE, Berti F: Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology 1999, 140:4024-4031.
23. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S: A role for ghrelin in the central regulation of feeding. Nature 2001, 409:194-198.
24. Tschop M, Smiley DL, Heiman ML: Ghrelin induces adiposity in rodents. Nature 2000, 407:908-913.
25. Deghenghi R, Cananzi MM, Torsello A, Battisti C, Muller EE, Locatelli V: GH-releasing activity of hexarelin. A new growth hormone releasing peptide, in infants and adult rats. Life Sci 1994, 54:1321-1328.
26. Locatelli V, Torsello A: Growth hormone secretagogues: focus on the growth hormone releasing peptides. Pharmacol Res 1997, 36:415-423.
27. Smith RG, Cheng K, Schoen WR, Pong SS, Hickey G, Jacks T: A nonpeptidyl growth hormone secretagogue. Science 1993, 260:1640-1643.
28. Howard AD, Fieghner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI: A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996, 273:974-977.
29. Sachs G, Zeng N, Prinz C: Physiology of isolated gastric endocrine cells. Annu Rev Physiol 1997, 59:234-256.
30. Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T, Matsukura S, Kangawa K, Nakazato M: Ghrelin, a novel growth hormones-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000, 141:4255-4261.
31. Hosoda H, Kojima M, Matsuo H, Kangawa K: Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun 2000, 279:909-913.
32. Ariyasu H, Takaya K, Tagami T, Ogawa Y, Hosoda K, Akamizu T, Suda M, Koh T, Natsui K, Toyooka S et al.: Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 2001, 86:4753-4758.
33. Takaya K, Ariyasu H, Kanamoto N, Iwakura H, Yoshimoto A, Harada M, Mori K, Komatsu Y, Usui T, Shimatsu A et al.: Ghrelin strongly stimulates growth hormone (GH) release in humans. J Clin Endocrinol Metab 2000, 85:4908-4911.
34. Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A, Matsuo H, Kangawa K, Nakazato M: The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 2002, 123:1120-1128.
35. Toshinai K, Mondal MS, Nakazato M, Date Y, Murakami N, Kojima M, Kangawa K, Matsukura S: Upregulation of ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. Biochem Biophys Res Commun 2001, 281:1220-1225.
36. Nakagawa E, Nagaya N, Okumura H, Enomoto M, Oya H, Ono F, Hosoda H, Kojima M, Kangawa K: Hyperglycaemia suppresses the secretion of ghrelin, a novel growth-hormone-releasing peptide: responses to the intravenous and oral administration of glucose. Clin Sci (Lond) 2002, 103:325-328.
37. Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, Kennedy AR, Roberts GH, Morgan DG, Ghatei MA et al.: The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 2000, 141:4325-4328.
38. Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N, Makino S, Fujimiya M, Niijima A, Fujino MA et al.: Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 2001, 120:337-345.
39. Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, Takaya K, Hayashi T, Inoue G, Hosoda K, Kojima M et al.: Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 2001, 50:227-232.
40. Nagaya N, Uematsu M, Kojima M, Date Y, Nakazato M, Okumura H, Hosoda H, Shimizu W, Yamagishi M, Oya H et al.: Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation 2001, 104:2034-2038.
41. Katugampola SD, Pallikaros Z, Davenport AP: [125I-His(9)]-ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue: up-regulation of receptors with athersclerosis. Br J Pharmacol 2001, 134:143-149.
42. Okumura H, Nagaya N, Enomoto M, Nakagawa E, Oya H, Kangawa K: Vasodilatory effect of ghrelin, an endogenous peptide from the stomach. J Cardiovasc Pharmacol 2002, 39:779-783.
43. Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F, Shimizu W, Hosoda H, Hirota Y, Ishida H, Mori H et al.: Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 2001, 104:1430-1435.
44. Wiley KE, Davenport AP: Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1. Br J Pharmacol 2002, 136:1146-1152.
45. Nagaya N, Miyatake K, Uematsu M, Oya H, Shimizu W, Hosoda H, Kojima M, Nakanishi N, Mori H, Kangawa K: Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure. J Clin Endocrinol Metab 2001, 86:5854-5859.
46. Dec GW, Fuster V: Idiopathic dilated cardiomyopathy. N Engl J Med 1994, 331:1564-1575.
47. Yang R, Bunting S, Gillett N, Clark R, Jin H: Growth hormone improves cardiac performance in experimental heart failure. Circulation 1995, 92:262-267.
48. Cittadini A, Stromer H, Katz SE, Clark R, Moses AC, Morgan JP, Douglas PS: Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat: a combined in vivo and in vitro evaluation. Circulation 1996, 93:800-809.
49. Fazio S, Sabatini D, Capaldo B, Vigorito C, Giordano A, Guida R, Pardo F, Biondi B, Sacca L: A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996, 334:809-814.
50. Nagaya N, Uematsu M, KojimaM, Ikeda Y, Yoshihara F, Shimizu W, Hosoda H, Hirota Y, Ishida H, Mori H et al.: Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 2001, 104:1430-1435.
51. Boger RH, Skamira C, Bode-Boger SM, Brabant G, von zur Muhlen A, Frolich JC: Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency: a double-blind, placebo-controlled study. J Clin Invest 1996, 98:2706-2713.
52. Tajima M, Weinberg EO, Bartunek J, Jin H, Yang R, Paoni NF, Lorell BH: Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with postinfarction heart failure. Circulation 1999, 99:127-134.
53. Cittadini A, Grossman JD, Napoli R, Katz SE, Stromer H, Smith RJ, Clark R, Morgan JP, Douglas PS: Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction. J Am Coll Cardiol 1997, 29:1109-1116.
54. Osterziel KJ, Strohm O, Schuler J, Friedrich M, Hanlein D, Willenbrock R, Anker SD, Poole-Wilson PA, Ranke MB, Dietz R: Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998, 351:1233-1237.
55. Isgaard J, Bergh CH, Caidahl K, Lomsky M, Hjalmarson A, Bengtsson BA: A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur Heart J 1998, 19:1704-1711.